Convatec Raises Full-Year Outlook as Shares Surge
Convatec said year-to-date organic revenue growth reached 3.7%, or 6.6% excluding InnovaMatrix. It cited strength in infusion care, including growth in diabetes and AbbVie’s Parkinson’s treatment.
Updating on trading over the last 10 months, the medical products and technology firm said year-to-date organic revenue growth had reached 3.7%, or 6.6% once InnovaMatrix was stripped out.In particular, it flagged "notable strength" in infusion care, driven by growth in diabetes and AbbVie’s Parkin…